Michael Lainchbury
AstraZeneca (United Kingdom)(GB)AstraZeneca (Singapore)(SG)AstraZeneca (Brazil)(BR)AstraZeneca (Germany)(DE)
Publications by Year
Research Areas
Ubiquitin and proteasome pathways, ATP Synthase and ATPases Research, DNA Repair Mechanisms, Cancer-related Molecular Pathways, Computational Drug Discovery Methods
Most-Cited Works
- → A Protecting Group Free Synthesis of (±)-Neostenine via the [5 + 2] Photocycloaddition of Maleimides(2008)96 cited
- → CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs(2012)92 cited
- → The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma(2015)68 cited
- → Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation(2014)61 cited
- → Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study(2015)56 cited
- → Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1)(2021)42 cited